Trials / Completed
CompletedNCT00543231
A Phase I Study of G3139 Subcutaneous in Solid Tumors
A Pharmacokinetic and Safety Assessment of G3139 Administered by Subcutaneous Injection to Patients With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (estimated)
- Sponsor
- Genta Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Genasense® is currently administered to subjects in clinical studies as a multiple-day continuous intravenous infusion. Subjects are treated on an outpatient basis and carry a pump that delivers the drug through a peripheral or central intravenous line. The route of administration limits the convenience of treatment, and catheter-related complications have been reported. This study is designed to evaluate the pharmacokinetics and safety of G3139 administered by subcutaneuous injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide |
Timeline
- Start date
- 2005-12-01
- Completion
- 2006-12-01
- First posted
- 2007-10-12
- Last updated
- 2007-10-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00543231. Inclusion in this directory is not an endorsement.